Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 316 participants.

Also called NCT01512979

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 316 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01512979
  • EudraCT 2011-004158-24
Other papers using this trial's data
  • Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia Postgraduate medicine, 2016-11 DOI, PubMed 27684308

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, India, Israel, Malaysia, Mexico, Philippines, Puerto Rico, Russia, Sri Lanka, Thailand, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01512979. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-05-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
metformin
Intervention (Drug)
linagliptin
Intervention (Drug)
metformin placebo
Intervention (Drug)
metformin placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01512979
Content hash
0f07bae52905a651abf20070c7d186ea513539bf89726f50c4bab15828d06d38